Abstract 400P
Background
Breast cancer is the leading killer of female cancer patient. Lung cancer became the second affecting cancer (12%) but the main killer (25%) in female cancer patient. (Cancer fact and Figures 2017” report published by American Cancer Society) and odd of getting lung cancer are 1 in 17. In Bangladesh, the status and features of female lung cancer is not clear. In western country, female are more prone to lung cancer due to some risk factor like smoking, alcohol, exposure of radon etc than Bangladesh. We tried to find out the socio-demographic status and clinical features of lung cancer of female in Bangladesh.
Methods
This was a descriptive comparative observational study on 2396 female cancer patients reached at Outpatient of Medical oncology department of National Institute of cancer Research and Hospital, Mohakhali, Bangladesh from January 2018 to December 2018. Patients were selected purposive sampling method.
Results
Total number of 2396 female patients were included in this study. The average age of female lung cancer patient was 56.12 years and average weight was 45.32kg. We had found 336 lung cancer patients (14%) among the 2396 female cancer patient. 58% were adenocarcinoma, 26% were Squamous Cell, 7% small cell variety with undifferentiated and others like Sarcoma, mesothelioma etc were 9%. Most of the patients were illiterate (59%) and 79% patient were poor or below average economically. 42% female patient didn’t have any habitual problem. 46.82%% patients had the battle nut/ Jarda, 7.65% were smoker, about 10% had more than one habitual issue. At the time of presentation none of the had ECOG 0, patients had performance status O, most of the patient’s performance status (ECOG) were 1 (58%) ECOG2 were 27%. 39% patient had comorbidity, among them most frequent comorbidity was Hypertension which was 39% and second was DM (33%) and 20% patient having more than one comorbidity.
Conclusions
The percentage of female lung cancer in Bangladesh is pretty high among female cancer patient. female are most vulnerable group in rural area as well as they need special attention. Moreover, female lung cancer with other comorbidities makes the treatment more complicated for the cancer physician as well as brings the worst outcome. So, female lung cancer management should be personalized and comprehensive.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
27P - The prognostic value of neutrophil to lymphocyte ratio (NLR) and 18F-FDG PET SUV in breast cancer patients underwent neoadjuvant chemotherapy
Presenter: Soong June Bae
Session: Poster display session
Resources:
Abstract
28P - Accuracy of core biopsy in predicting pathologic complete response in the breast in patients with complete/near complete clinical and radiological response (Complete Responders in the Breast – CRBr): A feasibility study
Presenter: Nisha Hariharan
Session: Poster display session
Resources:
Abstract
29P - Tumour response to neoadjuvant chemotherapy in breast cancer: Routine pathologic markers improve the predictive power of a cell-loss metric based on release of thymidine kinase 1 into blood
Presenter: Bernhard Tribukait
Session: Poster display session
Resources:
Abstract
30P - Comparison of metabolic changes between neoadjuvant chemotherapy and neoadjuvant endocrine therapy in premenopausal women with ER positive, HER2 negative breast cancer
Presenter: Ho-hyun Ryu
Session: Poster display session
Resources:
Abstract
31P - Circulating miR-155 as a potential therapeutic monitoring marker in breast cancer
Presenter: Sumadi Lukman Anwar
Session: Poster display session
Resources:
Abstract
32P - Profile of breast cancer epidemiology in Sanglah General Hospital, Denpasar, Bali from 2012 to 2019
Presenter: Citra Aryanti
Session: Poster display session
Resources:
Abstract
33P - Contrast enhanced chest CT in patients with breast cancer: Comprehensive imaging analysis and correlation with biological markers
Presenter: Bo Hwa Choi
Session: Poster display session
Resources:
Abstract
34P - Verification of metabolic regulatory mechanisms in androgen receptor-positive triple negative breast cancer
Presenter: Yuka Asano
Session: Poster display session
Resources:
Abstract
35TiP - Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2– inoperable locally advanced breast cancer (ABC): RIGHT choice study
Presenter: Yen-Shen Lu
Session: Poster display session
Resources:
Abstract
36TiP - A prospective study to assess response to neoadjuvant hormonal therapy in postmenopausal women with hormone-receptor positive breast cancer at a regional cancer centre in South India
Presenter: Shina Goyal
Session: Poster display session
Resources:
Abstract